As TREM2+ macrophages have been implicated in pathophysiological tissue remodeling involving aberrant lipid metabolism, our results indicate that TM4SF19 might be targeted for treating a large class of obesity-associated metabolic diseases. Here, TREM2 is linked to obesity due to melanocortin 4 receptor deficiency.